PROFUSA, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
PROFUSA, INC. (PFSA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-19
- PROFUSA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.40M.
- PROFUSA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$172.00K, a 21735.22% decline year-over-year.
- PROFUSA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $795.00.
- PROFUSA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$137.88K.
- PROFUSA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$188.97K.
- PROFUSA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$547.74K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 8 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.06M 10-Q · filed 2026-08-19 | ||||||||
| 2026-03-31 | -$1.40M 10-Q · filed 2026-05-15 | ||||||||
| 2025-12-31 | $1.59M S-1/A · filed 2026-05-01 | ||||||||
| 2025-09-30 | $2.82M 10-Q · filed 2025-11-19 | ||||||||
| 2025-06-30 | -$152.00K 10-Q · filed 2026-08-19 | -$14.45K 10-Q · filed 2025-08-14 | |||||||
| 2025-03-31 | -$172.00K 10-Q · filed 2026-05-15 | $2.25K 10-Q · filed 2025-06-13 | |||||||
| 2024-12-31 | $49.00K S-1/A · filed 2026-05-01 | $11.69K 10-K · filed 2025-03-31 | |||||||
| 2024-09-30 | -$2.00K 10-Q · filed 2025-11-19 | -$3.99K 10-Q · filed 2024-12-17 | |||||||
| 2024-06-30 | $1.98K 10-Q · filed 2025-08-14 | ||||||||
| 2024-03-31 | $795.00 10-Q · filed 2025-06-13 | ||||||||
| 2023-12-31 | -$188.97K 10-K · filed 2025-03-31 | ||||||||
| 2023-09-30 | -$176.14K 10-Q · filed 2024-12-17 | ||||||||
| 2023-06-30 | -$187.68K 10-Q · filed 2024-11-15 | ||||||||
| 2023-03-31 | -$137.88K 10-Q · filed 2024-10-09 | ||||||||
| 2022-12-31 | -$547.74K 10-K · filed 2024-02-26 | ||||||||
| 2022-09-30 | -$368.36K 10-Q · filed 2023-11-20 | ||||||||
| 2022-06-30 | -$260.50K 10-Q · filed 2023-08-14 | ||||||||
| 2022-03-31 | -$230.35K 10-Q · filed 2023-05-17 | ||||||||
| 2021-12-31 | $741.23K 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |